The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

The age-adjusted cancer death rate has fallen since the 1990s, with the world winning the so-called "war on cancer." ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early ...

A recent trial reveals that targeted stereotactic radiation significantly reduces neurologic death rates in small cell lung ...

The 32-year-old went 6-22 over parts of four seasons, the first three in Baltimore, before leaving the game to focus on his health.

The purpose of these estimates is to inform state and local cancer care organizations and providers, patient support programs and educators, advocates, and researchers so they can allocate resources ...